截至6月30日，金迪克股东户数4525.00，较上期增加6.27%；人均流通股27226股，较上期减少5.90%。 2025年1月-6月，金迪克实现营业收入352.42万元，同比增长7.18%；归母净利润-3965.31万元，同比增 长2.97%。 10月9日，金迪克跌1.15%，成交额1444.34万元。两融数据显示，当日金迪克获融资买入额63.49万元， 融资偿还60.66万元，融资净买入2.83万元。截至10月9日，金迪克融资融券余额合计2035.22万元。 融资方面，金迪克当日融资买入63.49万元。当前融资余额2035.22万元，占流通市值的1.07%，融资余 额低于近一年30%分位水平，处于低位。 融券方面，金迪克10月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量0.00股，融券余额0.00元，超过近一年80%分位水平，处于高位。 资料显示，江苏金迪克生物技术股份有限公司位于江苏省泰州市郁金路12号，成立日期2008年12月29 日，上市日期2021年8月2日，公司主营业务涉及专注于人用疫苗研发、生产、销售的生物制药企业。主 营业务收入构成为：疫苗产 ...

Group 1 - The report highlights that Chinese "manufacturing hard consumption" companies are entering a golden development period for globalization, transitioning from "product export" to "brand export" due to technological accumulation, supply chain advantages, and global layout [1][2] - The Chinese government has introduced favorable policies to support the globalization of manufacturing hard consumption enterprises, including guidance on brand internationalization and cross-border trade facilitation [2][3] - In 2024, policy support will focus on cross-border e-commerce and overseas warehouse construction, addressing challenges in overseas storage and distribution for enterprises [3][4] Group 2 - Chinese manufacturing hard consumption enterprises have developed a multi-faceted overseas expansion model characterized by "technological breakthroughs, localized production, and brand upgrades," with significant global factory layouts [3][4] - The innovation capabilities of Chinese companies in the consumer electronics and smart hardware sectors are gaining global recognition, with products like robotic vacuum cleaners and portable chargers consistently ranking as best sellers on cross-border e-commerce platforms [4][5] - The report identifies three major opportunities for the globalization of Chinese manufacturing hard consumption during the 15th Five-Year Plan period: the release of demand in emerging markets, product premiumization driven by technological upgrades, and the improvement of cross-border e-commerce and overseas warehouse systems [5][6] Group 3 - The globalization of Chinese manufacturing hard consumption is evolving from simple "product output" to "standard output" and "service output," with companies participating in the formulation of global industry standards and establishing comprehensive after-sales service networks [5][6] - The report emphasizes that the globalization journey of Chinese manufacturing hard consumption enterprises has entered a new phase, supported by policies, industrial foundations, and innovation vitality, positioning them as key players in the global consumption market [6][7] - The report outlines a comprehensive policy framework to support the internationalization of the domestic consumption industry, facilitating the transition from "product export" to "capacity export" and "brand export" [24][25]

每经头条（nbdtoutiao）——重磅解读！中国将不寻求WTO新的特殊和差别待遇，意味着什么？ （记者 王晓波） 每经AI快讯，金迪克9月30日晚间发布公告称，江苏金迪克生物技术股份有限公司董事会于近日收到公 司副总经理宋斌先生提交的辞职报告，宋斌先生因个人原因申请辞去副总经理职务，辞职后不再担任公 司任何职务。 ...

江苏金迪克生物技术股份有限公司 关于高级管理人员辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688670 证券简称：金迪克 公告编号：2025-025 | 姓名 | 离任职务 | 离任时间 | | 原定任期到 | | | 离任 | 是否继续在 上市公司及 | 具体职 务（如适 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 期日 | | | 原因 | 其控股子公 | 用） | 毕的公开 | | | | | | | | | | 司任职 | | 承诺 | | 宋斌 | 副总经理 | 2025 | 年 9 月 | 2026 年 | 5 | 月 | 个人 | 否 | 不适用 | 否 | | | | 30 | 日 | 10 | 日 | | 原因 | | | | 二、高级管理人员离任对公司的影响 宋斌先生已做好工作交接，其辞职不会对公司的生产经营造成不利影响。截 ...

近日，江苏金迪克生物技术股份有限公司董事会收到副总经理宋斌的辞职报告。宋斌因个人原因申请辞 去副总经理职务，辞职后不再担任公司任何职务。其原定任期到2026年5月10日，实际离任时间为2025 年9月30日。宋斌已做好工作交接，辞职不会对公司生产经营造成不利影响，截至公告披露日，他未持 有公司股票，也无未履行的承诺事项。 ...

Group 1 - The core point of the news is the decline in the stock price of Jindike Biotech, which fell by 5.05% to 14.66 CNY per share, with a total market capitalization of 1.806 billion CNY [1] - Jindike Biotech, established on December 29, 2008, focuses on the research, production, and sales of human vaccines, with 100% of its revenue derived from vaccine products [1] - The trading volume for Jindike Biotech was 6.309 million CNY, with a turnover rate of 0.34% [1] Group 2 - The Qianhai Kaiyuan Fund holds a significant position in Jindike Biotech, with 13,700 shares representing 1.11% of the fund's net value, making it the fifth-largest holding [2] - The fund, named Qianhai Kaiyuan Strong Consensus 100 Strong Stocks (001849), has a total scale of 17.2629 million CNY and has achieved a year-to-date return of 10.03% [2] - Over the past year, the fund has recorded a return of 30.13%, ranking 3212 out of 3814 in its category [2] Group 3 - The fund manager of Qianhai Kaiyuan Strong Consensus 100 Strong Stocks is Yuan Yichun, who has been in the position for 3 years and 38 days [3] - The total asset size of the fund is 67.572 million CNY, with the best return during Yuan's tenure being -9.11% and the worst being -26.57% [3]

中国经济网北京9月15日讯金迪克(688670.SH)近日披露2025年半年度报告显示，报告期内，公司实现营业收 入352.42万元，同比增加7.18%；实现归属于母公司所有者的净利润-3965.31万元；实现归属于母公司所有 者的扣除非经常性损益的净利润-4294.08万元；经营活动产生的现金流量净额-8548.81万元。 | 主要会计数据 | 本报告期 (1-6月) | 上年同期 | 本报告期比上年 同期增减(%) | | --- | --- | --- | --- | | 营业收入 | 3,524,238.84 | 3,288,169.37 | 7.18 | | 利润息额 | -50,899,286.11 | -48,684,708.94 | 不适用 | | 归属于上市公司股东的净利润 | -39,653,098.13 | -40,867,089.23 | 不适用 | | 归属于上市公司股东的扣除非经常性 损益的净利润 | -42,940,823.45 | -47,145,812.18 | 不适用 | | 经营活动产生的现金流量净额 | -85,488,113.52 | -89,270,106.59 | ...

Group 1 - The Chinese government will include the HPV vaccine in the national immunization program, aiming to protect women's health and potentially eliminate cervical cancer by 2050 [1] - The inclusion of the HPV vaccine is expected to provide significant cost-effectiveness in preventing cervical cancer among adolescent females [1] Group 2 - Reports indicate that the Trump administration may consider an executive order to impose stricter restrictions on experimental drugs and clinical data from China, which has led to a decline in the stock prices of innovative drug companies in A-shares and H-shares [2] - However, some institutions believe that these restrictions may be mere posturing, as the development of Chinese innovative drugs continues to accelerate, with improvements in pipeline quantity and quality [2] Group 3 - Wang Chen has been removed from his position as Vice President of the Chinese Academy of Engineering, with the reasons for his dismissal remaining unclear [3] - Wang Chen is a prominent expert in respiratory medicine and has been involved in significant medical projects, which have previously sparked controversy [3] Group 4 - Zhang Jianhui, the General Manager of Jindike, passed away due to illness, marking a significant loss for the company and highlighting the risks associated with reliance on key individuals in the biotech sector [4] Group 5 - Qianhong Pharmaceutical received a regulatory letter due to its actual controller's failure to comply with disclosure obligations after increasing shareholding beyond the stipulated threshold [5] - The incident reflects potential internal control weaknesses within Qianhong Pharmaceutical [5]

11日上午，国务院新闻办公室举行"高质量完成'十四五'规划"系列主题新闻发布会，介绍"十四五"时期 卫生健康工作发展成就。据介绍，今年国家将推出面向适龄女生的HPV疫苗接种服务，并将HPV疫苗纳 入国家免疫规划，保护女性健康。 每经记者｜陈星 每经编辑｜董兴生 点评：青少年女性接种HPV疫苗，最具有宫颈癌防治的成本效益。随着我国将HPV疫苗纳入国家免疫规 划，或将有助于实现在2050年基本消除宫颈癌的目标。 ｜ 2025年9月12日 星期五 ｜ NO.2 特朗普政府或加强对中国药品限制？机构：虚张声势！ NO.1 HPV疫苗将纳入国家免疫规划 9月11日，A股、H股创新药概念集体走低。消息面上，有媒体报道称，特朗普政府正研议一项行政命 令，打算严格限制来自中国的实验性药物与临床数据，以应对中国生物科技崛起对美国产业的威胁。对 此消息，相关机构表示，这一"限制"或为虚张声势。中国创新药从管线价值到临床验证、BD出海、商 业化逐步兑现，从跟跑到并跑、再到领跑全球，管线数量、质量大幅提升。中国创新药发展趋势加速， 产业逻辑不变，BD仍在加速，景气度持续向上。 点评：该行政令草案的影响存在不确定性，首先其是否能落地是 ...

Core Viewpoint - The passing of Zhang Jianhui, the general manager of Jindike, is a significant event for the company, as he played a crucial role in its development and management [1][3]. Group 1: Company Leadership and Contributions - Zhang Jianhui was a major shareholder of Jindike since 2015 and was appointed as the general manager in October 2023 [3]. - He was recognized for his diligent work and significant contributions to the company's growth during his tenure [3]. - The board and employees expressed deep condolences and gratitude for his efforts [3]. Group 2: Shareholding and Financial Performance - As of the announcement date, Zhang held over 5.68 million shares, accounting for 4.61% of the total share capital, making him the third-largest shareholder [3][4]. - In the first half of 2025, Jindike reported a revenue of 3.5242 million yuan, a year-on-year increase of 7.18%, while the net profit attributable to shareholders was a loss of 39.6531 million yuan, a reduction in loss of 2.97% compared to the previous year [5]. Group 3: Company Operations and Market Position - Jindike's operations remain normal following Zhang's passing, with the board appointing Yu Jun to act as the general manager temporarily [4]. - As of September 10, 2023, Jindike's stock price was 15.96 yuan per share, with a total market capitalization of approximately 2 billion yuan [6].